<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27357" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Community-Acquired Pneumonia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Regunath</surname>
            <given-names>Hariharan</given-names>
          </name>
          <aff>University of Maryland - Baltimore Washington Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Oba</surname>
            <given-names>Yuji</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hariharan Regunath declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yuji Oba declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27357.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>This comprehensive course covers the diverse facets of community-acquired pneumonia, a prevalent cause of hospitalization, mortality, and substantial healthcare expenditure. The spectrum of this disease ranges from mild cases managed as outpatients to severe conditions necessitating intensive care unit intervention. Throughout this activity, participants focus on the nuances of community-acquired pneumonia evaluation and treatment. Learners gain the knowledge and skills necessary for early diagnosis and timely determination of the appropriate level of care&#x02014;crucial factors in enhancing patient outcomes.</p>
        <p>A key emphasis of this course lies in understanding the pivotal role played by the interprofessional team in evaluating and treating patients with community-acquired pneumonia. By engaging in interdisciplinary collaboration, learners gain insights into how different healthcare professionals contribute to a holistic approach to managing this condition. This collaborative model not only enhances patient care but also significantly improves the competence of individual team members.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the varied community-acquired pneumonia presentations to facilitate early and accurate diagnosis.</p></list-item><list-item><p>Differentiate between bacterial and viral etiologies of&#x000a0;community-aquired pneumonia&#x000a0;through a comprehensive assessment of patient history, physical examination findings, and relevant diagnostic tests.</p></list-item><list-item><p>Apply appropriate antibiotic stewardship principles in the management of community-acquired pneumonia, ensuring optimal antimicrobial selection, dosage, and duration to minimize resistance and adverse effects.</p></list-item><list-item><p>Collaborate with interprofessional healthcare team memebers, including respiratory therapists, pharmacists, and infection control specialists, to optimize the comprehensive care of patients with community-acquired pneumonia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27357&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27357">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27357.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Community-acquired pneumonia is a leading cause of hospitalization and mortality and incurs significant healthcare costs. As disease presentation varies from a mild illness that can be managed as an outpatient to a severe illness requiring treatment in the intensive care unit, diagnosing early and determining the appropriate level of care is important for improving outcomes.<xref ref-type="bibr" rid="article-27357.r1">[1]</xref><xref ref-type="bibr" rid="article-27357.r2">[2]</xref><xref ref-type="bibr" rid="article-27357.r3">[3]</xref><xref ref-type="bibr" rid="article-27357.r4">[4]</xref><xref ref-type="bibr" rid="article-27357.r5">[5]</xref></p>
      </sec>
      <sec id="article-27357.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Many pathogens cause community-acquired pneumonia, including bacteria, viruses, and fungi.<xref ref-type="bibr" rid="article-27357.r6">[6]</xref>&#x000a0;Common bacterial pathogens can be classified as:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gram-positive agents such as&#x000a0;<italic toggle="yes">Streptococcus pneumoniae</italic>,&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>, group A streptococci, and other streptococci&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Gram-negative agents such as&#x000a0;<italic toggle="yes">Haemophilus influenzae</italic>,&#x000a0;<italic toggle="yes">Moraxella catarrhalis</italic>, and Enterobacteriaceae</p>
          </list-item>
          <list-item>
            <p>Atypical agents such as&#x000a0;<italic toggle="yes">Legionella, Mycoplasma, Chlamydia pneumoniae,&#x000a0;</italic>and&#x000a0;<italic toggle="yes">Chlamydia psittaci&#x000a0;</italic><xref ref-type="bibr" rid="article-27357.r7">[7]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Among viruses, rhinovirus, influenza, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and other respiratory viruses (parainfluenza, respiratory syncytial virus, human metapneumovirus, etc) have become increasingly detected as pathogens based on molecular detection methods. Worldwide,&#x000a0;<italic toggle="yes">S pneumoniae</italic>&#x000a0;and&#x000a0;<italic toggle="yes">H influenzae</italic>&#x000a0;are still the leading causes of acute bacterial pneumonia (see <bold>Image.</bold> Mycobacterium Avium-Intracellulare Pneumonia). The most recent population-based active surveillance in the United States identified that human rhinovirus, influenza virus, and&#x000a0;<italic toggle="yes">S pneumoniae were the most common pathogens.</italic><xref ref-type="bibr" rid="article-27357.r8">[8]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-27357.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years and is affected by geography, season, and population characteristics.<xref ref-type="bibr" rid="article-27357.r5">[5]</xref>&#x000a0;In the US the annual incidence is 24.8 cases per 10,000 adults, with higher rates as age increases.&#x000a0;Pneumonia is the eighth leading cause of death and first among infectious causes of death. The mortality rate is as high as 23% for patients admitted to the intensive care unit for severe pneumonia.</p>
        <p>All patients with comorbid illness are considered at risk for pneumonia, but specific risk factors exist for particular pathogens. Drug-resistant pneumococci are more likely in:</p>
        <list list-type="bullet">
          <list-item>
            <p>Those older than 65</p>
          </list-item>
          <list-item>
            <p>Children in daycare centers</p>
          </list-item>
          <list-item>
            <p>Those who have taken beta-lactam antibiotics in the previous 90 days</p>
          </list-item>
          <list-item>
            <p>Individuals with alcohol use disorder, chronic medical conditions, and immune suppression</p>
          </list-item>
        </list>
        <p>Pseudomonas pneumonia is more likely in those with:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bronchiectasis</p>
          </list-item>
          <list-item>
            <p>Malnutrition</p>
          </list-item>
          <list-item>
            <p>Corticosteroid therapy</p>
          </list-item>
          <list-item>
            <p>Antibiotic intake for greater than 7 days in the preceding month</p>
          </list-item>
        </list>
        <p>Other etiological clues from geographic regions include the following:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Coccidioidomycosis in the Southwestern US</p>
          </list-item>
          <list-item>
            <p>Blastomycosis or histoplasmosis in the states of the Ohio River valley bird exposures for&#x000a0;<italic toggle="yes">Chlamydia psittaci</italic></p>
          </list-item>
          <list-item>
            <p>Contact with flea-infested or infected rodents or rabbits during outside activities such as lawn mowing in the Northeast US (Martha's Vineyard, Cape Cod, etc) for tularemia pneumonia&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27357.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Pathogens initially colonize the pharynx, followed by micro-aspiration, which is the mechanism of entry into the lower respiratory tract. Once there, the pathogen induces the host's pulmonary defense. If there is a defect in the host's defense or it is overcome by high inoculum or virulence of the pathogen, then pneumonia will result. Pathogens may also spread through the hematogenous route and macro-aspiration.</p>
      </sec>
      <sec id="article-27357.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Common symptoms of pneumonia include fever, chills, cough productive of purulent sputum, dyspnea, pleuritic chest pain, and weight loss. Patients with alcohol use disorder and those who are immune-compromised may have an absence of fever and less evident or systemic symptoms such as weakness, lethargy, altered mental status, dyspepsia, or other upper gastrointestinal symptoms. The presence of some symptoms may provide etiological clues. For example, diarrhea, headache, and confusion (related to hyponatremia) can indicate&#x000a0;<italic toggle="yes">Legionella </italic>infection;&#x000a0;otitis media, Stevens-Johnson syndrome, or anemia with jaundice (hemolytic anemia) may indicate&#x000a0;<italic toggle="yes">Mycoplasma </italic>infection<italic toggle="yes">.&#x000a0;</italic>Pneumonia can provoke acute decompensation of an underlying chronic illness, such as congestive heart failure, and can confound the initial presentation of pneumonia and result in delays in diagnosis and treatment.</p>
      </sec>
      <sec id="article-27357.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Initial workup for pneumonia will include imaging and blood work (see <bold>Images.</bold> Lung Abscess, Computed Tomography Scan and Bilateral Pneumonia,<bold>&#x000a0;</bold>Computed Tomography Scan and Lung Pneumonia with Fibrosis).&#x000a0;A chest x-ray will be needed to identify an infiltrate or effusion, which, if present, will improve diagnostic accuracy (see <bold>Image.</bold> Healthy Lung and Q Fever Pneumatic Lung, Chest X-ray). Bloodwork should include a complete blood count with differentials; serum electrolytes with renal and liver function tests help confirm evidence of inflammation and assess severity. Influenza testing is recommended during the winter season. Testing for respiratory viruses on nasopharyngeal swabs by molecular methods can be considered if available.</p>
        <p>Tools such as CURB 65 (confusion, urea greater than or equal to 20 mg/dL, respiratory rate greater than or equal to 30/min, blood pressure systolic less than 90 mm Hg or diastolic less than 60 mm Hg), and Pneumonia Severity Index for severity assessment may assist in determining the treatment setting, such as outpatient versus inpatient. Still, accuracy is limited when used alone or without practical clinical judgment.</p>
        <p>In hospitalized patients, blood and sputum cultures should be collected, preferably before the institution of antimicrobial therapy, but without delay in treatment. If cultures are negative, urine collection and testing for<italic toggle="yes">&#x000a0;</italic>legionella<italic toggle="yes">&#x000a0;</italic>and pneumococcal antigens must be considered as they aid in diagnosis. In the presence of confounding comorbidities, such as congestive heart failure, serum procalcitonin levels can be used as a biomarker to initiate and guide antimicrobial therapy. Serology for tularemia, endemic mycoses, or&#x000a0;<italic toggle="yes">C psittaci</italic>&#x000a0;can be evaluated in the presence of epidemiologic clues.<xref ref-type="bibr" rid="article-27357.r9">[9]</xref><xref ref-type="bibr" rid="article-27357.r10">[10]</xref><xref ref-type="bibr" rid="article-27357.r11">[11]</xref></p>
      </sec>
      <sec id="article-27357.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Monotherapy with a macrolide (erythromycin, azithromycin, or clarithromycin) or doxycycline is recommended in the outpatient setting. In the presence of comorbid illness (chronic heart disease excluding hypertension); chronic lung disease (chronic obstructive pulmonary disease and asthma); chronic liver disease; chronic alcohol use disorder; diabetes mellitus; smoking; splenectomy; human immunodeficiency virus (or other immunosuppression); a respiratory fluoroquinolone (high-dose levofloxacin, moxifloxacin, gemifloxacin); a combination of oral beta-lactam (high dose amoxicillin or amoxicillin-clavulanate, cefuroxime, cefpodoxime); and macrolide is recommended.<xref ref-type="bibr" rid="article-27357.r11">[11]</xref><xref ref-type="bibr" rid="article-27357.r12">[12]</xref><xref ref-type="bibr" rid="article-27357.r13">[13]</xref><xref ref-type="bibr" rid="article-27357.r14">[14]</xref></p>
        <p>Inpatient management is recommended for patients with a CURB 65 score greater than or equal to 2. A respiratory fluoroquinolone monotherapy or combination therapy with beta-lactam (cefotaxime, ceftriaxone, ampicillin-sulbactam, or ertapenem) and macrolide are recommended options for non-intensive care settings.</p>
        <p>Admission to the intensive care unit must be considered in patients with 3 or more signs of early deterioration. These include respiratory rate greater than 30, PaO<sub>2</sub>/FiO<sub>2</sub> less than or equal to 250, multilobar infiltrates, encephalopathy, thrombocytopenia, hypothermia, leucopenia, and hypotension. Combination therapy with a beta-lactam and either a macrolide or a respiratory fluoroquinolone is recommended. In patients with suspected aspiration, ampicillin-sulbactam or ertapenem can be used. Monotherapy is not recommended.</p>
        <p>If risk factors for Pseudomonas are present, then antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, ceftazidime, meropenem, imipenem) along with either an antipseudomonal fluoroquinolone (ciprofloxacin or levofloxacin) or a combination of aminoglycoside and azithromycin are recommended. Vancomycin or linezolid should be added if community-acquired methicillin-resistant&#x000a0;<italic toggle="yes">S aureus&#x000a0;</italic>is a consideration.&#x000a0;</p>
        <p>The recommended duration of therapy is 5 to 7 days in patients with a favorable clinical response, such as the absence of fever for more than 48 to 72 hours, not requiring supplemental oxygen, and resolution of tachycardia, tachypnea, or hypotension. Prolongation of therapy is indicated in patients with a delayed response, specific bacterial pathogens such as Pseudomonas (14-21 days) or&#x000a0;<italic toggle="yes">S aureus</italic>&#x000a0;(7-21 days), or Legionella pneumonia (14 days), and for complications such as empyema, lung abscess, or necrotizing pneumonia. Chest tube placement will be needed to drain an empyema, and in cases with multiple loculations, a surgical decortication may be needed. A 14-day therapy with macrolide or doxycycline will treat tularemia pneumonia or psittacosis, and itraconazole is the drug of choice for pneumonia caused by coccidioidomycosis or histoplasmosis.</p>
        <p>A 5-day therapy with oseltamivir is recommended for all patients who test positive for the influenza virus and present within 48 hours of symptom onset; there is no benefit to oseltamivir if started beyond 48 hours after symptom onset. Still, any hospitalized patients with influenza must be treated with this agent regardless of the presentation time from the beginning of the illness.&#x000a0;</p>
        <p>Intravenous glucocorticoids can be considered adjunctive therapy in critically ill patients with severe community-acquired pneumonia without risk factors for adverse outcomes from using steroids (eg, influenza infection). They are associated with reductions in short-term mortality and duration of intensive care days.<xref ref-type="bibr" rid="article-27357.r15">[15]</xref><xref ref-type="bibr" rid="article-27357.r16">[16]</xref><xref ref-type="bibr" rid="article-27357.r17">[17]</xref><xref ref-type="bibr" rid="article-27357.r18">[18]</xref></p>
      </sec>
      <sec id="article-27357.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnoses for community-acquired pneumonia include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute bronchitis</p>
          </list-item>
          <list-item>
            <p>Acute exacerbation of chronic bronchitis</p>
          </list-item>
          <list-item>
            <p>Aspiration pneumonitis</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure and pulmonary edema</p>
          </list-item>
          <list-item>
            <p>Pulmonary fibrosis</p>
          </list-item>
          <list-item>
            <p>Myocardial infarction</p>
          </list-item>
          <list-item>
            <p>Systemic lupus erythematosus pneumonitis</p>
          </list-item>
          <list-item>
            <p>Pulmonary drug hypersensitivity reactions (nitrofurantoin, daptomycin)</p>
          </list-item>
          <list-item>
            <p>Drug-induced pulmonary disease (bleomycin)</p>
          </list-item>
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Cryptogenic organizing pneumonia</p>
          </list-item>
          <list-item>
            <p>Pulmonary embolus</p>
          </list-item>
          <list-item>
            <p>Pulmonary infarction</p>
          </list-item>
          <list-item>
            <p>Bronchogenic carcinomas</p>
          </list-item>
          <list-item>
            <p>Granulomatosis with polyangiitis (Wegener granulomatosis)</p>
          </list-item>
          <list-item>
            <p>Lymphoma</p>
          </list-item>
          <list-item>
            <p>Tracheobronchitis</p>
          </list-item>
          <list-item>
            <p>Radiation pneumonitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27357.s10" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Vaccine recommendations evolve in parallel with changing epidemiology vaccine developments and formulation advancements. All adults 65 years and older and those younger than 65 and considered at risk for pneumonia must receive a pneumococcal vaccination (PCV). The 2 vaccines used until 2021 were the pneumococcal polysaccharide vaccine (PPSV) 23 and PCV13. In summer 2021, the US FDA approved 2 additional preparations, PCV20 and PCV15, for adult vaccinations. Since then, the Advisory Committee on Immunization Practices (ACIP) recommendations favored using these latter formulations for adult vaccinations. Current ACIP recommendations for previously unvaccinated, non-immune-compromised individuals who are at least aged 65 years, as well as those between 19 to 64 years with risk factors for pneumonia, receive either PCV20 alone or PCV15 coupled with PPSV23 one year later.</p>
        <p>For adults who already had vaccinations with prior formulations (PCV13 or PPSV23), subsequent options are different. Those who received only PCV13 can be followed by PPSV23 vaccination a year later. If the prior vaccine was only with PPSV23, then after a year, either PCV20 alone or PCV15 followed a year later with another PPSV23 can be given. The 1-year interval between pneumococcal doses can be shortened to 8 weeks for immunocompromised individuals.</p>
        <p>Influenza vaccination is recommended for all adult patients at risk for influenza-related complications. Inactivated flu shots (trivalent or quadrivalent, egg-based or recombinant) are usually recommended for adults. Live attenuated intranasal vaccine can be given to healthy, nonpregnant adults under 49. This is contraindicated in pregnancy, the immune-suppressed and health care workers caring for them, and in those with comorbidities.</p>
        <p>COVID-19 vaccination is recommended for all non-immune-compromised adults with either a single dose of a 2023-24 mRNA vaccine regardless of previous vaccination and that it be given at least 2 months after the most recent prior dose of COVID-19 vaccine. Novavax (protein-based) vaccine is given in 2 doses separated by 3 to 8 weeks for unvaccinated individuals. In contrast, a single dose after 2 months of the last dose is sufficient for those previously vaccinated with any other formulation of the COVID-19 vaccine. For individuals with moderate to severe immune compromise, 3 or 4 vaccine doses are recommended, with at least one using an mRNA formulation. A vaccine against respiratory syncytial virus is recommended for adults over 60 who may be at risk for severe disease.</p>
      </sec>
      <sec id="article-27357.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with community-acquired pneumonia may present to the clinician or the emergency department. The medical staff should be aware of the signs and symptoms associated with pneumonia. Working together, the healthcare team will improve outcomes. Members can include primary care, emergency department personnel, specialists, nurses, and pharmacists. Most patients respond to outpatient antibiotic therapy for 5 to 7 days. Patients who are short of breath, febrile, and in respiratory distress need to be admitted. An infectious disease or pulmonology consult is recommended if the diagnosis is unclear. Some patients may present with a parapneumonic effusion, which may require drainage. Typically, nurses monitor the patients and report current status and updates to the rest of the team. Pharmacists evaluate medication choices, check for allergies and drug interactions, and educate patients about possible side effects and the importance of compliance.</p>
        <p>The providers should encourage all patients to get the annual influenza vaccine. In addition, all adults 65 and older and those considered at risk for pneumonia must receive the pneumococcal vaccination. The outcomes in most patients with community-acquired pneumonia are favorable.<xref ref-type="bibr" rid="article-27357.r19">[19]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-27357.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27357&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27357">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/community-acquired-pneumonia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27357">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27357/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27357">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27357.s13">
        <fig id="article-27357.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Computed Tomography of a Lung Abscess. The thick-walled cavitary lesion in the right lung is an abscess. The diffuse ground glass infiltrates seen in both lungs represent pneumonia. Yale Rosen, Public Domain, via Wikimedia Commons (CC by 4.0)&#x000a0;</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Lung_abscess_-_CT_scan_x7471756882x" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27357.s14">
        <fig id="article-27357.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Healthy Lung and Q Fever Pneumatic Lung, Chest X-ray. X-ray A represents a normal healthy lung; X-ray B represents a lung with Q fever pneumonia. Hehkuviini, Public Domain, via <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://commons.wikimedia.org/wiki/File:Pneumonia_x-ray.jpg">Wikimedia Commons</ext-link>.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="358px-Pneumonia_x-ray" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27357.s15">
        <fig id="article-27357.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Bilateral Pneumonia, Computed Tomography Scan. Bilateral pneumonia with abscesses, effusions, and cavers in an adult male. Christaras A, Public Domain, via Wikimedia Commons (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/2.5/deed.en">CC by 2.5</ext-link>).</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CT_chest_in_pneumonia_with_abscesses_caverns_and_effusions_d0" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27357.s16">
        <fig id="article-27357.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Chest X-ray of Mycobacterium Avium-Intracellulare Pneumonia. Contributed by&#x000a0;S Bhimji, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAI__pneumonia" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27357.s17">
        <fig id="article-27357.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Lung Pneumonia With Fibrosis. Contributed by Fabiola Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="673-20005" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27357.s18">
        <title>References</title>
        <ref id="article-27357.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical prognostic significance of serum high mobility group box-1 protein in patients with community-acquired pneumonia.</article-title>
            <source>J Int Med Res</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>1232</fpage>
            <page-range>1232-1240</page-range>
            <pub-id pub-id-type="pmid">30732500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tesfay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Degafu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bekele</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ayalew</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gedefaw</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tadesse</surname>
                <given-names>BT</given-names>
              </name>
            </person-group>
            <article-title>Radiologic Diagnosis and Hospitalization among Children with Severe Community Acquired Pneumonia: A Prospective Cohort Study.</article-title>
            <source>Biomed Res Int</source>
            <year>2019</year>
            <volume>2019</volume>
            <fpage>6202405</fpage>
            <pub-id pub-id-type="pmid">30729128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alshahwan</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Alsowailmi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alsahli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alotaibi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alshaikh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Almajed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Omair</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Almodaimegh</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The prevalence of complications of pneumonia among adults admitted to a tertiary care center in Riyadh from 2010-2017.</article-title>
            <source>Ann Saudi Med</source>
            <year>2019</year>
            <season>Jan-Feb</season>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-36</page-range>
            <pub-id pub-id-type="pmid">30712048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>XK</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>L&#x000fc;</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>QZ</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Scored minor criteria for severe community-acquired pneumonia predicted better.</article-title>
            <source>Respir Res</source>
            <year>2019</year>
            <month>Jan</month>
            <day>31</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <pub-id pub-id-type="pmid">30704469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsoumani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Salomonsson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bencina</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Clinical, economic, and humanistic burden of community acquired pneumonia in Europe: a systematic literature review.</article-title>
            <source>Expert Rev Vaccines</source>
            <year>2023</year>
            <season>Jan-Dec</season>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>876</fpage>
            <page-range>876-884</page-range>
            <pub-id pub-id-type="pmid">37823894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gadsby</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Musher</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>The Microbial Etiology of Community-Acquired Pneumonia in Adults: from Classical Bacteriology to Host Transcriptional Signatures.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2022</year>
            <month>Dec</month>
            <day>21</day>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>e0001522</fpage>
            <pub-id pub-id-type="pmid">36165783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>File</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Community-Acquired Pneumonia. Reply.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Oct</month>
            <day>26</day>
            <volume>389</volume>
            <issue>17</issue>
            <fpage>1633</fpage>
            <page-range>1633-1634</page-range>
            <pub-id pub-id-type="pmid">37888934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Self</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Wunderink</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Fakhran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Balk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bramley</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grijalva</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Courtney</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Chappell</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hart</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Trabue</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Donnelly</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Ampofo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Waterer</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lindstrom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Winchell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Erdman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>McCullers</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Pavia</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Finelli</surname>
                <given-names>L</given-names>
              </name>
              <collab>CDC EPIC Study Team</collab>
            </person-group>
            <article-title>Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Jul</month>
            <day>30</day>
            <volume>373</volume>
            <issue>5</issue>
            <fpage>415</fpage>
            <page-range>415-27</page-range>
            <pub-id pub-id-type="pmid">26172429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chalmers</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Dela Cruz</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Domined&#x000f2;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kollef</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martin-Loeches</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Niederman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wunderink</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Challenges in severe community-acquired pneumonia: a point-of-view review.</article-title>
            <source>Intensive Care Med</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-171</page-range>
            <pub-id pub-id-type="pmid">30706119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pickens</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Wunderink</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Principles and Practice of Antibiotic Stewardship in the ICU.</article-title>
            <source>Chest</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>156</volume>
            <issue>1</issue>
            <fpage>163</fpage>
            <page-range>163-171</page-range>
            <pub-id pub-id-type="pmid">30689983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nuttall</surname>
                <given-names>JJC</given-names>
              </name>
            </person-group>
            <article-title>Current antimicrobial management of community-acquired pneumonia in HIV-infected children.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>5</issue>
            <fpage>595</fpage>
            <page-range>595-608</page-range>
            <pub-id pub-id-type="pmid">30664362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Froes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>P&#x000f3;voa</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Outpatient management of community-acquired pneumonia.</article-title>
            <source>Curr Opin Pulm Med</source>
            <year>2019</year>
            <month>May</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>249</fpage>
            <page-range>249-256</page-range>
            <pub-id pub-id-type="pmid">30585861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The drug use to treat community-acquired pneumonia in children: A cross-sectional study in China.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>97</volume>
            <issue>46</issue>
            <fpage>e13224</fpage>
            <pub-id pub-id-type="pmid">30431600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hagel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moeser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pletz</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>[Management of community acquired pneumonia].</article-title>
            <source>MMW Fortschr Med</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>160</volume>
            <issue>19</issue>
            <fpage>52</fpage>
            <page-range>52-61</page-range>
            <pub-id pub-id-type="pmid">30406515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meduri</surname>
                <given-names>GU</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Bridges</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>El-Solh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seam</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Davis-Karim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Umberger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anzueto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sriram</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Restrepo</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Guardiola</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Buck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Suffredini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Uyeda</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>GD</given-names>
              </name>
              <collab>ESCAPe Study Group</collab>
            </person-group>
            <article-title>Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia.</article-title>
            <source>Intensive Care Med</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>48</volume>
            <issue>8</issue>
            <fpage>1009</fpage>
            <page-range>1009-1023</page-range>
            <pub-id pub-id-type="pmid">35723686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dequin</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Meziani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Quenot</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kamel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ricard</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Badie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reignier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heming</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Plantef&#x000e8;ve</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Souweine</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Voiriot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Colin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Frat</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Mira</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Barbarot</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fran&#x000e7;ois</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Louis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gibot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guitton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giacardi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hraiech</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vimeux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>L'Her</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Faure</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Herbrecht</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bouisse</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Joret</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Terzi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gacouin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quentin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jourdain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leclerc</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coffre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bourgoin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lengell&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caille-F&#x000e9;n&#x000e9;rol</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giraudeau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Le Gouge</surname>
                <given-names>A</given-names>
              </name>
              <collab>CRICS-TriGGERSep Network</collab>
            </person-group>
            <article-title>Hydrocortisone in Severe Community-Acquired Pneumonia.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>May</month>
            <day>25</day>
            <volume>388</volume>
            <issue>21</issue>
            <fpage>1931</fpage>
            <page-range>1931-1941</page-range>
            <pub-id pub-id-type="pmid">36942789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pracher</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sawodny</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Blaschke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gelbenegger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Radtke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zeitlinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jorda</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Corticosteroid Therapy for Community-Acquired Pneumonia: A Meta-Analysis and Meta-Regression of Randomized, Controlled Trials.</article-title>
            <source>Clin Infect Dis</source>
            <year>2023</year>
            <month>Dec</month>
            <day>15</day>
            <volume>77</volume>
            <issue>12</issue>
            <fpage>1704</fpage>
            <page-range>1704-1713</page-range>
            <pub-id pub-id-type="pmid">37876267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Clinical value of glucocorticoids for severe community-acquired pneumonia: A systematic review and meta-analysis based on randomized controlled trials.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2023</year>
            <month>Nov</month>
            <day>17</day>
            <volume>102</volume>
            <issue>46</issue>
            <fpage>e36047</fpage>
            <pub-id pub-id-type="pmid">37986401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27357.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Espinoza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>JRLE</given-names>
              </name>
              <name>
                <surname>Bergmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Oliveira Melo</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Calil</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Salluh</surname>
                <given-names>JIF</given-names>
              </name>
            </person-group>
            <article-title>Factors associated with mortality in severe community-acquired pneumonia: A multicenter cohort study.</article-title>
            <source>J Crit Care</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>50</volume>
            <fpage>82</fpage>
            <page-range>82-86</page-range>
            <pub-id pub-id-type="pmid">30502687</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
